Acurx: KIPO grantes new patent covering DNA Polymerase IIIC inhibitors

Acurx (ACXP) Pharmaceuticals announced that the Korean Intellectual Property Office has granted a new patent which covers DNA Polymerase IIIC inhibitors including compositions-of-matter, methods of use, and pharmaceutical compositions, which further strengthen Acurx’s intellectual property portfolio and represents the most recent addition to its expanding series of granted patents in the U.S. and abroad. To date, Acurx has secured four U.S. patents, along with granted patents in Israel, Japan, India, Australia and Korea, all of which protect key aspects of the company’s ACX-375C program targeting DNA Polymerase IIIC. Additional country-level patent applications remain under review.